Cantor Fitzgerald Investment Advisors L.P. Buys 548 Shares of Bristol Myers Squibb Company $BMY

Cantor Fitzgerald Investment Advisors L.P. increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 271,448 shares of the biopharmaceutical company’s stock after buying an additional 548 shares during the period. Cantor Fitzgerald Investment Advisors L.P.’s holdings in Bristol Myers Squibb were worth $12,565,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Brighton Jones LLC lifted its holdings in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. NBC Securities Inc. increased its holdings in Bristol Myers Squibb by 102,110.0% during the 1st quarter. NBC Securities Inc. now owns 10,221 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 10,211 shares during the period. Merit Financial Group LLC raised its position in shares of Bristol Myers Squibb by 21.6% in the first quarter. Merit Financial Group LLC now owns 51,601 shares of the biopharmaceutical company’s stock worth $3,147,000 after buying an additional 9,166 shares in the last quarter. RFG Advisory LLC grew its holdings in shares of Bristol Myers Squibb by 67.1% during the first quarter. RFG Advisory LLC now owns 27,915 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 11,208 shares in the last quarter. Finally, Bremer Bank National Association purchased a new position in Bristol Myers Squibb in the 1st quarter worth approximately $200,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $47.39 on Thursday. The stock has a 50 day moving average of $46.49 and a 200 day moving average of $48.85. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The firm has a market cap of $96.47 billion, a PE ratio of 19.11, a PEG ratio of 2.31 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the previous year, the business earned $2.07 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.2%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent research reports. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. Citigroup cut their price objective on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.